StockData
Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc. (LRMR) stock

LRMRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$2.99−0.01 (-0.33%)

Close on Nov 17, 2026Market cap $310.61MP/E –Yield –

Larimar Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Larimar Therapeutics's total debt was $6.75M at Mar 31, 2020. For fiscal 2019 it was $8.46M, down 44.3% from the year before. The highest annual figure on record is $20.00M in fiscal 2017.

Annual total debt

PeriodPeriod endValueChange
FY2019Dec 31, 2019$8.46M-44.3%
FY2018Dec 31, 2018$15.19M-24.1%
FY2017Dec 31, 2017$20.00M+479.2%
FY2015Dec 31, 2015$3.45M-44.1%
FY2014Dec 31, 2014$6.18M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2020Mar 31, 2020$6.75M-50.1%
Q4 FY2019Dec 31, 2019$8.46M-44.3%
Q3 FY2019Sep 30, 2019$10.17M-39.6%
Q2 FY2019Jun 30, 2019$11.85M-35.9%
Q1 FY2019Mar 31, 2019$13.53M-32.9%
Q4 FY2018Dec 31, 2018$15.19M-24.1%
Q3 FY2018Sep 30, 2018$16.84M+1303.7%
Q2 FY2018Jun 30, 2018$18.50M–
Q1 FY2018Mar 31, 2018$20.16M–
Q4 FY2017Dec 31, 2017$20.00M–
Q3 FY2016Sep 30, 2016$1.20M–

More Larimar Therapeutics figures

See a number that looks wrong?